skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8830

A systematic review of new advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): focus on galsulfase

Review

(2579) Views  (753) Full article downloads

Authors: Regina P El Dib, Gregory M Pastores

Published Date September 2009 Volume 2009:3 Pages 459 - 468
DOI: http://dx.doi.org/10.2147/BTT.S3766

Regina P El Dib1, Gregory M Pastores2

1Department of Surgery, McMaster University, McMaster Institute of Urology, Hamilton, Ontario, Canada; 2Department of Neurology and Pediatrics, New York University School of Medicine, New York, NY, USA

Introduction: Mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy syndrome) is an autosomal recessive lysosomal storage disorder, characterized primarily by skeletal dysplasia and joint contracture. It is caused by a deficiency of N-acetylgalactosamine-4-sulfatase (arylsulfatase B), for which a recombinant formulation (galsulfase) is available as replacement therapy.

Objective: To evaluate the effectiveness and safety of galsulfase compared to placebo or no interventions, for treating MPS VI. We also considered studies evaluating different doses of galsulfase.

Methods: A systematic review of the literature was conducted. A computerized electronic search in MEDLINE, EMBASE, CENTRAL, SciELO, and LILACS was carried on to identify any randomized trials that met our inclusion criteria.

Results: Two studies were included in the review. Because the number of studies was small, our analysis probably did not find any statistically significant difference. Long-term follow-up will be required to ascertain full clinical benefit, on both event-free survival and quality of life measures.

Conclusions: There is some evidence to support the use of galsulfase in the treatment of MPS VI; however due to the very low quantity of included studies we could not analyze it in an appropriate way. This review highlights the need for continued research into the use of enzyme replacement therapy for MPS VI.

Keywords: mucopolysaccharidosis VI, Maroteaux-Lamy syndrome, galsulfase, naglazyme, systematic review








Readers of this article also read:

Therapeutic vaccines for malignant brain tumors
Finding a new drug and vaccine for emerging swine flu: What is the concept?
Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers
Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies
Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
Potential role of ustekinumab in the treatment of chronic plaque psoriasis
Palliative treatment of malignant ascites: profile of catumaxomab
Managing idiopathic short stature: role of somatropin (rDNA origin) for injection
New and emerging treatment approaches to lupus
Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • Journal Indexing

    See where all the Dove Press journals are indexed